Moody's Ratings (Moody's) affirmed the ratings of Bristol-Myers Squibb Company ("Bristol") including the A2 senior unsecured long-term ratings, the Prime-1 commercial paper rating, the A2 rating on the senior unsecured revolving credit facility, the (P)A2 senior unsecured shelf rating, the (P)A3 sub...
Global oncology spending is projected to reach US$409bn by 2028E, up from US$223bn in 2023A at a 5yr CAGR of 11.5-14.5% from 2024-2028 (IQVIA, 2024). This growth is in part driven by US spending, which has increased to $99bn in 2023A up from $65bn in 2019A - the US makes up ~45% of global oncology spending.
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
Moody's Investors Service ("Moody's") assigned an A2 rating to the new senior unsecured notes issuance of Bristol-Myers Squibb Company ("Bristol"). There are no changes to Bristol's existing ratings including the A2 senior unsecured ratings and the outlook remains unchanged at negative. Proceeds o...
Moody's Investors Service ("Moody's") confirmed the ratings of Bristol-Myers Squibb Company ("Bristol"). The ratings confirmed include the A2 ratings on senior unsecured bonds and a senior unsecured revolving credit facility, the (P)A2 senior unsecured shelf rating, the (P)A3 subordinated shelf rati...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.